192 related articles for article (PubMed ID: 11431323)
1. Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma.
Sonoda Y; Ozawa T; Hirose Y; Aldape KD; McMahon M; Berger MS; Pieper RO
Cancer Res; 2001 Jul; 61(13):4956-60. PubMed ID: 11431323
[TBL] [Abstract][Full Text] [Related]
2. Enumeration of the simian virus 40 early region elements necessary for human cell transformation.
Hahn WC; Dessain SK; Brooks MW; King JE; Elenbaas B; Sabatini DM; DeCaprio JA; Weinberg RA
Mol Cell Biol; 2002 Apr; 22(7):2111-23. PubMed ID: 11884599
[TBL] [Abstract][Full Text] [Related]
3. Pathological and molecular progression of astrocytomas in a GFAP:12 V-Ha-Ras mouse astrocytoma model.
Shannon P; Sabha N; Lau N; Kamnasaran D; Gutmann DH; Guha A
Am J Pathol; 2005 Sep; 167(3):859-67. PubMed ID: 16127163
[TBL] [Abstract][Full Text] [Related]
4. GATA6 is an astrocytoma tumor suppressor gene identified by gene trapping of mouse glioma model.
Kamnasaran D; Qian B; Hawkins C; Stanford WL; Guha A
Proc Natl Acad Sci U S A; 2007 May; 104(19):8053-8. PubMed ID: 17463088
[TBL] [Abstract][Full Text] [Related]
5. Expression of mutant p53 proteins implicates a lineage relationship between neural stem cells and malignant astrocytic glioma in a murine model.
Wang Y; Yang J; Zheng H; Tomasek GJ; Zhang P; McKeever PE; Lee EY; Zhu Y
Cancer Cell; 2009 Jun; 15(6):514-26. PubMed ID: 19477430
[TBL] [Abstract][Full Text] [Related]
6. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype.
Turcan S; Rohle D; Goenka A; Walsh LA; Fang F; Yilmaz E; Campos C; Fabius AW; Lu C; Ward PS; Thompson CB; Kaufman A; Guryanova O; Levine R; Heguy A; Viale A; Morris LG; Huse JT; Mellinghoff IK; Chan TA
Nature; 2012 Feb; 483(7390):479-83. PubMed ID: 22343889
[TBL] [Abstract][Full Text] [Related]
7. Akt pathway activation converts anaplastic astrocytoma to glioblastoma multiforme in a human astrocyte model of glioma.
Sonoda Y; Ozawa T; Aldape KD; Deen DF; Berger MS; Pieper RO
Cancer Res; 2001 Sep; 61(18):6674-8. PubMed ID: 11559533
[TBL] [Abstract][Full Text] [Related]
8. Metabolic reprogramming in mutant IDH1 glioma cells.
Izquierdo-Garcia JL; Viswanath P; Eriksson P; Chaumeil MM; Pieper RO; Phillips JJ; Ronen SM
PLoS One; 2015; 10(2):e0118781. PubMed ID: 25706986
[TBL] [Abstract][Full Text] [Related]
9. IDH mutation impairs histone demethylation and results in a block to cell differentiation.
Lu C; Ward PS; Kapoor GS; Rohle D; Turcan S; Abdel-Wahab O; Edwards CR; Khanin R; Figueroa ME; Melnick A; Wellen KE; O'Rourke DM; Berger SL; Chan TA; Levine RL; Mellinghoff IK; Thompson CB
Nature; 2012 Feb; 483(7390):474-8. PubMed ID: 22343901
[TBL] [Abstract][Full Text] [Related]
10. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation.
Koivunen P; Lee S; Duncan CG; Lopez G; Lu G; Ramkissoon S; Losman JA; Joensuu P; Bergmann U; Gross S; Travins J; Weiss S; Looper R; Ligon KL; Verhaak RG; Yan H; Kaelin WG
Nature; 2012 Feb; 483(7390):484-8. PubMed ID: 22343896
[TBL] [Abstract][Full Text] [Related]
11. Mutant IDH1-driven cellular transformation increases RAD51-mediated homologous recombination and temozolomide resistance.
Ohba S; Mukherjee J; See WL; Pieper RO
Cancer Res; 2014 Sep; 74(17):4836-44. PubMed ID: 25035396
[TBL] [Abstract][Full Text] [Related]
12. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal.
Killela PJ; Reitman ZJ; Jiao Y; Bettegowda C; Agrawal N; Diaz LA; Friedman AH; Friedman H; Gallia GL; Giovanella BC; Grollman AP; He TC; He Y; Hruban RH; Jallo GI; Mandahl N; Meeker AK; Mertens F; Netto GJ; Rasheed BA; Riggins GJ; Rosenquist TA; Schiffman M; Shih IeM; Theodorescu D; Torbenson MS; Velculescu VE; Wang TL; Wentzensen N; Wood LD; Zhang M; McLendon RE; Bigner DD; Kinzler KW; Vogelstein B; Papadopoulos N; Yan H
Proc Natl Acad Sci U S A; 2013 Apr; 110(15):6021-6. PubMed ID: 23530248
[TBL] [Abstract][Full Text] [Related]
13. IDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo.
Bralten LB; Kloosterhof NK; Balvers R; Sacchetti A; Lapre L; Lamfers M; Leenstra S; de Jonge H; Kros JM; Jansen EE; Struys EA; Jakobs C; Salomons GS; Diks SH; Peppelenbosch M; Kremer A; Hoogenraad CC; Smitt PA; French PJ
Ann Neurol; 2011 Mar; 69(3):455-63. PubMed ID: 21446021
[TBL] [Abstract][Full Text] [Related]
14. Spontaneous in vitro senescence of glioma cells confirmed by an antibody against IDH1R132H.
Stoczynska-Fidelus E; Och W; Rieske P; Bienkowski M; Banaszczyk M; Winiecka-Klimek M; Zieba J; Janik K; Rosiak K; Treda C; Stawski R; Radomiak-Zaluska A; Piaskowski S
Anticancer Res; 2014 Jun; 34(6):2859-67. PubMed ID: 24922649
[TBL] [Abstract][Full Text] [Related]
15. Interfacing Sca-1(pos) mesenchymal stem cells with biocompatible scaffolds with different chemical composition and geometry.
Forte G; Franzese O; Pagliari S; Pagliari F; Di Francesco AM; Cossa P; Laudisi A; Fiaccavento R; Minieri M; Bonmassar E; Di Nardo P
J Biomed Biotechnol; 2009; 2009():910610. PubMed ID: 19644551
[TBL] [Abstract][Full Text] [Related]
16. Trans-lesion synthesis and mismatch repair pathway crosstalk defines chemoresistance and hypermutation mechanisms in glioblastoma.
Cheng X; An J; Lou J; Gu Q; Ding W; Droby GN; Wang Y; Wang C; Gao Y; Anand JR; Shelton A; Satterlee AB; Mann B; Hsiao YC; Liu CW; Lu K; Hingtgen S; Wang J; Liu Z; Miller CR; Wu D; Vaziri C; Yang Y
Nat Commun; 2024 Mar; 15(1):1957. PubMed ID: 38438348
[TBL] [Abstract][Full Text] [Related]
17. Trans-Lesion Synthesis and Mismatch Repair Pathway Crosstalk Defines Chemoresistance and Hypermutation Mechanisms in Glioblastoma.
Cheng X; An J; Lou J; Gu Q; Ding W; Droby G; Wang Y; Wang C; Gao Y; Shelton A; Satterlee AB; Mann BE; Hsiao YC; Liu CW; Liu K; Hingtgen S; Wang J; Liu Z; Miller R; Wu D; Vaziri C; Yang Y
bioRxiv; 2023 Oct; ():. PubMed ID: 37905107
[TBL] [Abstract][Full Text] [Related]
18. HOXDeRNA activates a cancerous transcription program and super-enhancers genome-wide.
Deforzh E; Kharel P; Karelin A; Ivanov P; Krichevsky AM
bioRxiv; 2023 Jun; ():. PubMed ID: 37425921
[TBL] [Abstract][Full Text] [Related]
19. Multi-Omic Analysis of CIC's Functional Networks Reveals Novel Interaction Partners and a Potential Role in Mitotic Fidelity.
Takemon Y; LeBlanc VG; Song J; Chan SY; Lee SD; Trinh DL; Ahmad ST; Brothers WR; Corbett RD; Gagliardi A; Moradian A; Cairncross JG; Yip S; Aparicio SAJR; Chan JA; Hughes CS; Morin GB; Gorski SM; Chittaranjan S; Marra MA
Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345142
[No Abstract] [Full Text] [Related]
20. Haploinsufficiency of NFKBIA reshapes the epigenome antipodal to the IDH mutation and imparts disease fate in diffuse gliomas.
Bredel M; Espinosa L; Kim H; Scholtens DM; McElroy JP; Rajbhandari R; Meng W; Kollmeyer TM; Malta TM; Quezada MA; Harsh GR; Lobo-Jarne T; Solé L; Merati A; Nagaraja S; Nair S; White JJ; Thudi NK; Fleming JL; Webb A; Natsume A; Ogawa S; Weber RG; Bertran J; Haque SJ; Hentschel B; Miller CR; Furnari FB; Chan TA; Grosu AL; Weller M; Barnholtz-Sloan JS; Monje M; Noushmehr H; Jenkins RB; Rogers CL; MacDonald DR; Pugh SL; Chakravarti A
Cell Rep Med; 2023 Jun; 4(6):101082. PubMed ID: 37343523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
